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INTERLEUKIN-6 ADMINISTRATION HAS NO 
ACUTE HEMODYNAMIC OR HEMATOLOGIC 
EFFECT IN THE DOG 
Jean-Charles Preiser/ Denis Schmartz,1 Philippe V an der Linden/ 
Jean Content/ Paul Vanden Bussche,Z Wim Buurman,3 Walter Sebald,4 
Etienne Dupont,5 Michael R. Pinsky,6 Jean-Louis Vincene·* 
To investigate the possible hemodynamic efl'ects of interleukin-6 (IL-6), a single dose of 15 
mcg/kg of recombinant IL-6 isolated from Escherichia coli was injected intravenously in six 
pentobarbital-anesthetized dogs. After 30 min, saline infusion was performed to maintain the -
pulmonary artery balloon-occluded pressure at baseline Ievel. The animals were observed for 
up to 5 hours. No other hemodynamic alteration was observed than a gradual decline in 
cardiac output attributed to anesthesia. Hematologic variables, blood glucose, and total 
serum proteins were also constant. IL-6 Ievels were markedly elevated in the blood, bot no 
tumor necrosis factor activity was detected. Thus a primary roJe for IL-6 in the early 
cardiovascular alterations associated with septic shock seems unlikely. 
Copyright© 1991 by W.B. Saunders Company 
Various cytokines have been implicated in the 
development of the hemodynamic alterations character-
izing severe sepsis. In particular tumor necrosis factor 
(TNF), interleukin-1 (IL-1 ), and interleukin-2 (IL-2) 
are released during severe infections or following 
intravenous challenge with endotoxin. If given by 
themselves, they have been shown to produce the 
decrease in arterial pressure, the increase in cardiac 
output, and the fall in systemic vascular resistance that 
characterize sepsis. 1-5 
Interleuk.in-6 (IL-6) is another mediator released 
by various cells under the influence of other cytokines 
Iike TNF and IL-1, bacterial products like endotoxin, 
and even viruses. 6-S IL-6 has various metabolic and 
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immunological effects, including the release of many 
metabolically active substances from the liver. In man, 
IL-6 is released following administration of endotoxin8 
or TNF.9 An association between IL-6levels and fatal 
outcome has been found in patients with septic shock 
(references 10 and 11, and M.R. Pinsky et al., unpub-
lished data). 
However, it is not known whether IL-6 participates 
in the hemodynamic disturbances associated with sep-
tic shock. Therefore, the present study evaluated the 
acute effects of IL-6 administration in a dog model. 
RESULTS 
The effects of IL-6 on the measured and derived 
hemodynamic variables are summarized in the Table 1. 
Intravenous fluid requirements were very limited to 
maintain the end-expiratory PA balloon-occluded pres-
sure (Ppao) at baseline Ievels (mean 7.1 ± 12.5 ml/kg/ 
h). Throughout the study, IL-6 administrationbad no 
hemodynamic effect other than a gradual decrease in 
cardiac output and a corresponding increase in sys-
temic vascular resistance. After a transient decline, the 
core temperature tended to rise during the last 2 h of 
the experim~nt. There was a small and non-significant 
increase in vo2 and 02 extraction, as weil as in white 
blood count (WBC). Blood glucose did not change. 
Serum IL-6 Ievels increased markedly in all ani-
mals but showed marked interanimal variability in 
Ievels (Table 2). No TNF activity was detected in the 
blood. 
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Table 1. Hemodynamic and metabolic efl'ects of IL-6 administration in the 6 dogs. 
Variable 
Blood temp, oc 
0 
(Baseline) 
37.3 ± 1.2 
30 60 
37.3 ± 1.2 37.3 ± 1.3 
Time (min) 
120 180 
37.1 ± 1.4 37.1 ± 1.4 
240 
37.4 ± 1.4 
300 
(4 dogs) 
37.9 ± 1.0 
Heart rate, bpm 128.2 ± 11.7 145.0 ± 11.5 137.0 ± 7.9 138.3 ± 14.6 127.0 ± 28.4 138.0 ± 30.8 147.5 ± 34.2 
Mean Art. P., mmHg 114.4 ± 26.7 106.9 ± 25.7 114.4 ± 25.6 119.9 ± 8.5 124.4 ± 8.6 122.4 ± 15.1 117.1 ± 17.3 
Pulm. Art. P., mmHg 11.1 ± 2.0 11.6 ± 0.9 11.4 ± 1.3 11.8 ± 0.9 13.4 ± 4.1 12.9 ± 0.8 13.6 ± 2.0 
Pulm. Art. Balloon-occl P., mmHg 4.0 ± 0.8 5.4 ± 1.5 4.5 ± 1.0 5.0 ± 1.2 5.3 ± 1.3 5.7 ± 0.8 5.8 ± 0.8 
Right Atrial P., mmHg 2.5 ± 1.0 2.8 ± 1.3 2.7 ± 1.4 3.3 ± 1.1 2.8 ± 0.7 3.0 ± 1.2 2.8 ± 0.4 
Cardiac output, L/min 6.0 ± 2.4 6.3 ± 1.4 5.3 ± 1.1 3.9 ± 0.5 3.5 ± 1.8 2.9* ± 0.9 3.5 ± 1.0 
Syst. Vase. Res, dynes sec cm-5 1692 ± 641 1342 ± 205 1690 ± 190 2393 ± 261 2900* ± 687 3555t ± 1196 2686 ± 475 
Pulm. Vase. Res, dynes sec cm-5 113.8 ± 54.3 85.7 ± 35.3 109.7 ± 31.8 142.0 ± 33.6 190.0 ± 58.1 216.6 ± 75.2 186.5 ± 38.9 
Left Ventr. Stroke Work, g.m. 72.3 ± 34.2 61.9 ± 22.8 60.2 ± 23.3 45.7 ± 12.1 47.6 ± 17.3 36.9 ± 20.8 42.4 ± 28.1 
Right Ventr. Stroke Work, g.m. 5.6 ± 2.6 5.2 ± 1.6 4.7 ± 1.5 3.3 ± 0.7 4.2 ± 1.8 3.0 ± 1.3 4.0 ± 2.4 
Pa02, mmHg 90.2 ± 0.2 92.1 ± 0.2 90.8 ± 0.2 95.4 ± 0.2 95.8 ± 0.1 93.3 ± 0.1 84.4 ± 0.1 
Hemoglobin conc., g/dl 12.0 ± 1.1 12.4 ± 0.7 12.7 ± 1.6 12.7 ± 0.9 12.6 ± 1.3 12.8 ± 1.4 12.5 ± 1.6 
0 2 Transport, ml/min 883 ± 340 984 ± 258 842 ± 221 631 ± 103 554 ± 123 468 ± 130 538 ± 148 
0 2 Consumption, ml/min 164± 48 221 ± 86 218 ± 80 273 ± 128 291 ± 121 336 ± 99 329 ± 114 
0 2 Extraction, % 0.28 ± 0.09 0.26 ± 0.08 0.30 ± 0.09 0.33 ± 0.09 0.34 ± 0.09 0.36 ± 0.06 0.36 ± 0.07 
Blood Lactate, mEq/L 1.34 ± 0.82 1.22 ± 0.67 1.23 ± 0.60 1.08 ± 0.51 1.22 ± 0.58 1.10 ± 0.57 0.95 ± 0.55 
Glucose, mgldl 173.0 ± 9.6 178.0 ± 21.5 178.5 ± 29.3 171.2 ± 18.8 161.7 ± 9.4 171.2 ± 8.4 180.8 ± 20.1 
Total protein, g/dl 7.50 ± 0.89 7.50 ± 0.91 7.58 ± 0.82 7.12 ± 0.71 7.15 ± 0.52 7.10 ± 0.44 7.15 ± 0.41 
Hematocrit, % 34.6 ± 2.8 35.3 ± 2.1 36.6 ± 4.4 36.8 ± 2.5 36.9 ± 3.5 37.5 ± 3.8 37.9 ± 5.7 
White blood cells/mm3 3.7 ± 3.1 3.8 ± 3.3 
Platelets/mm3 206 ± 45 183 ± 81 
•p < 0.05. 
tp < 0.01. 
DISCUSSION 
Severe sepsis can trigger the release of various 
inflammatory and immunological substances into the 
circulation, including peptides (bradykinin, hista-
mine ), eicosanoid metabolites (prostacyclin, thrombox-
ane A2, prostaglandin E2), and cytokines (TNF, IL-1, 
IL-2), all of which have been shown to either contrib-
ute to or mirnie specific aspects of the septic hemody-
namic response.1·5 IL-6 isanother cytokine that is also 
released into the circulation early in the course of 
human sepsis12.13 and may be involved in the resultant 
inflammatory and metabolic response. IL-6 stimulates 
hematopoiesis and production and release of acute 
phase proteins/4 and may stimulate adrenocorticotro-
Table 2. Serum IL-6levels (in U/ml) in the 6 dogs. 
Dog 0 
number (Baseline) 30 60 
1 13 5,368 3,391 
2 46 11,456 4,710 
3 28 1,677 640 
4 19 1,728 802 
5 5 304 165 
6 15 597 72 
Mean 21 3,522 1,630 
± SD 14 4,287 1,940 
4.8 ± 2.2 7.0 ± 5.2 6.2 ± 3.6 9.6 ± 6.1 11.2 ± 5.9 
173 ± 78 190 ± 43 150 ± 64 217 ± 27 207 ± 29 
pic hormone (AC1H) release and insulin resistance. 
However, the acute hemodynamic and hematologic 
effects of IL-6 are unknown. Based on the findings of 
this study, however, IL-6 has no significant acute 
hemodynamic or hematologic effects in the dog when 
given alone as a bolus. We did see a gradual and 
progressive decrease in cardiac output and an increase 
in systemic vascular resistance. This effect was most 
likely due to pentobarbital anesthesia. Furthermore, in 
the fluid resuscitated dog model, sepsis and sepsis-Iike 
syndromes are associated with an increase in cardiac 
output and a decrease in systemic vascular resistance. 
We can think of several possible reasons for our 
inability to observe any hemodynamic or hematologic 
effects of IL-6 in the dog. First, the amount of IL-6 may 
Time(min) 
120 180 240 300 
690 115 50 26 
6,969 2,223 1,552 
298 99 63 
391 156 72 26 
62 26 15 13 
17 14 13 5 
1,405 439 294 18 
2,737 876 617 10 
have been inadequate to induce any measurable effect, 
although Iarger doses would have. This seems unlikely 
since the dosage Ievel was chosen has been shown to 
induce metabolic effects in the rat, 15 and IL-6 blood 
Ievels were similar to those measured by us in the dog 
following endotoxin administration (5 mcg!kg) (unpub-
Iished data). So these Ievels seem appropriate. Second, 
the specific IL-6 used in this study may not be active in 
the dog. Species variability to susceptibility to endot-
oxin and cytokines is weil known. However, IL-6 is a 
small oligopeptide and does induce metabolic changes 
in a variety of animal species. Nevertheless, we cannot 
entirely exclude this possibility. Third, since we only 
noted the effects of IL-6 for the first 5 h following its 
infusion, if the metabolic effects of IL-6 determine any 
related hemodynamic ones, then we would not see 
them. However, it would be difficult to have an acute 
canine model of IL-6 infusion stable for Ionger periods 
of instrumentation. Furthermore, IL-6 release occurs 
early in the course of human septic shock, 12'13 usually 
within the first hour. If delayed actions do occur, it is 
unlikely that IL-6 is a primary mediator of the acute 
hemodynamic response to sepsis, but our data do not 
exclude the possibility that IL-6 is important in the 
overall response to established sepsis. Fourth, IL-6 
may require the interaction of other cytokines to be 
active. This seems reasonable, since it requires TNF 
and IL-1 for its release.9•10 Although clearly released 
during sepsis in association with other cytokines, and 
thus potentially requiring such cytokine interactions to 
be active, other cytokines, such as TNF, IL-1, and IL-2, 
have significant hemodynamic effects if given alone. 
IL-6 may exert systemic effects not measured in 
the present study. IL-6 may function more as an 
immunoregulating cytokine through the production of 
acute phase reaction proteins and cortisol release. 
These important metabolic regulatory effects of IL-6 
may occur during the acute phases of shock but might 
not alter any of the observed variables characterizing 
septic shock. Accordingly, on the basis of this study, a 
primary role of IL-6 in initiating the early hemody-
namic alterations associated with septic shock is un-
likely. 
MATERIAL AND METHODS 
Six large mongrel dogs (22 ± 4 kg) were anesthetized 
with pentobarbital sodium (25 mglkg IV, followed by a 
constant infusion of 4 mglkg/h), and their tracheas intubated 
and ventilated with room air. The details of the experimental 
setting have been previously described.16-18 Brietly, the animal 
was instrumented with arterial and venous catheters, and a 
pulmonary artery (PA) balloon-tipped catheter to allow 
measurements of arterial, right atrial, and PA pressures and 
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cardiac output by thermodilution and arterial and mixed 
venous blood gases. 
After baseline measurements following instrumenta-
tion, a single dose of 15 mcglkg of IL-6 was administered 
through the centrat venous catheter. Recombinant human 
IL-6 of full biological activity was isolated from Escherichia 
coli. 19 The concentration was 6.6 mg protein/ml 50% acetoni-
trol. (IL-6 was provided by W. Sebald). This dose of IL-6 has 
been shown to induce metabolic effects in previous animal 
experiments. 15 Thirty minutes following the infusions of IL-6, 
saline infusion was started to maintain an end-expiratory PA 
balloon-occluded pressure (Ppao) at baseline Ievel. There 
was no attempt to cantrot the temperature of the animal. 
Hemodynamic measurements and blood sampling were per-
formed at baseline,.after 30 min, 1, 2, 3, 4 (all dogs), and 5 h 
( 4 dogs ). Derived hemodynamic variables were calculated by 
standard formulae. 16"18 Appropriate blood samples were as-
sayed for arterial and mixed venous blood gases (IL 282 
Radiometer, Copenhagen), hemoglobin and hematocrit, white 
blood count (WBC), platelet count, blood Iactate ( enzymatic 
method), glucose (Dextrostix), and total proteins (refractom-
etry). Blood samples were also collected simultaneously in 
glass pyrogen-free tubes and stored at -70°C prior to 
measurement of serum IL-6 and TNF Ievels. Serum IL-6 
activity was assayed using an IL-6-dependent mause hybri-
doma, 7TD1, cultivated in flat-bottomed microtiter plates 
containing 2,000 cells per weil in the presence of serial 
dilutions of the serum sample. Mter 4 days of culture, the 
number of surviving cells was determined by a colorimetric 
assay for hexosaminidase, as previously described. 20 Hybri-
doma growth factor/IL-6 activity was expressed in U/ml 
defined as the dilution giving half maximal proliferation of 
7TD1 cells. One unit corresponds to approximately 5 pglml 
of IL-6. 7TD1 cells do not respond to TNF, IL-lß, IL-2, 
interferon a, ß, or -y, nor to any of the known colony-
stimulating factors other than IL-6.20 The biological activity 
of IL-6 samples was completely neutralized by adding mono-
specific rabbit polyclonal anti-recombinant human IL-6 anti-
badies to the test samples. The inter-assay variability ( ±30%) 
was corrected by the use of an internal standard. Each 
sample was tested at least four times. To eliminate inhibitory 
effects present in undiluted sera the samples were bathed at 
56°C for 30 min before the assay (J. Content). 
TNF Ievels were determined by a modified TNF-specific 
ELISA technique (W. Buurman). 
Statistical analysis was performed using an analysis of 
variance for repeated measures and a post-hoc Student-
Newman-Keuls test. An f ratio corresponding to a p value 
less than 0.05 was considered statistically significant. 
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